Supernus Announces Fourth Quarter and Full Year 2014 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Supernus Pharmaceuticals (SUPN) PT Raised to $16 at Piper Jaffray Post Q4
March 12, 2015 7:21 AM EDTPiper Jaffray analyst David Amsellem reiterated an Overweight rating and boosted his price target on Supernus Pharmaceuticals (NASDAQ: SUPN) to $16.00 (from $14.00) following Q4 results, noting continued strength for the epilepsy franchise.
Amsellem commented, "Supernus reported non-GAAP EPS of $0.08 on revenues of $31M, well... More
Supernus Pharma (SUPN) Tops Q4 EPS by 3c
March 10, 2015 5:01 PM EDTSupernus Pharma (NASDAQ: SUPN) reported Q4 EPS of ($0.10), $0.03 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $30.8 million versus the consensus estimate of $24.4 million.
For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.
... More